Nuclear transcription factor (TF) (TF)

Nuclear transcription factors are a diverse class of proteins that regulate gene expression by binding to specific DNA sequences, thereby controlling the transcription of genetic information from DNA to messenger RNA [1.1.2, 1.4.1]. They serve as critical convergence points for cellular signaling pathways and govern essential processes such as cell growth, differentiation, apoptosis, and immune responses [1.1.3, 1.2.4]. Dysregulation of these factors is central to the pathogenesis of various diseases, including cancer, where they often act as oncogenes or tumor suppressors, as well as inflammatory and metabolic disorders [1.2.5, 1.3.3]. While many transcription factors were historically considered 'undruggable' due to their lack of traditional binding pockets, the nuclear receptor subfamily has been successfully targeted by small-molecule ligands for decades [1.2.2, 1.4.1]. Examples of well-established targets within this class include the estrogen receptor in breast cancer and the glucocorticoid receptor in inflammatory conditions [1.2.1, 1.3.3]. Modern therapeutic approaches are expanding to include direct inhibitors of non-receptor factors, such as HIF-2α, and innovative strategies like proteolysis-targeting chimeras (PROTACs) to induce the degradation of specific transcription factor proteins [1.2.2, 1.3.3]. Additionally, indirect modulation through the inhibition of upstream kinases or the use of molecular glues is being explored to overcome the structural challenges of targeting these proteins [1.3.3, 1.4.1]. Despite their therapeutic potential, targeting transcription factors remains challenging due to their pleiotropic effects and the potential for significant off-target toxicity [1.2.2, 1.2.4].

Other names

Transcription factor [1.1.2]Sequence-specific DNA-binding factor [1.1.2]Gene regulatory protein [1.4.1]

Drugs targeting nuclear transcription factors typically function through competitive antagonism of ligand-binding domains (in nuclear receptors), inhibition of protein-protein or protein-DNA interactions, or the induction of targeted protein degradation via the ubiquitin-proteasome system [1.2.2, 1.2.5, 1.4.1].